Proanthocyanidin B2 (PB2), a major type of proanthocyanidins, has been reported to cross blood-brain-barrier and have potent inhibitory activity on Tau and Aβ aggregates for the treatment in AD. This evidence concerns the gene MAPT and Alzheimer disease.